Journal
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcimb.2021.765879
Keywords
Chagas disease; Trypanosoma cruzi; cardiomyopathy; immunomodulation; immunotherapy
Categories
Funding
- CNPq [304258/2019-9]
- FAPESB [PNX0002/2014]
Ask authors/readers for more resources
Chagas disease caused by Trypanosoma cruzi can lead to Chronic Chagas cardiomyopathy (CCC) with severe complications like arrhythmias, heart failure, and death. Despite over a hundred years of discovery, there is still no effective treatment, especially for CCC. Immunomodulatory agents are considered a rational alternative due to the systemic inflammation causing cardiac tissue damage, showing potential in modulating inflammation and improving myocarditis in CCC models.
Chagas disease is a parasitic infection caused by the intracellular protozoan Trypanosoma cruzi. Chronic Chagas cardiomyopathy (CCC) is the most severe manifestation of the disease, developed by approximately 20-40% of patients and characterized by occurrence of arrhythmias, heart failure and death. Despite having more than 100 years of discovery, Chagas disease remains without an effective treatment, especially for patients with CCC. Since the pathogenesis of CCC depends on a parasite-driven systemic inflammatory profile that leads to cardiac tissue damage, the use of immunomodulators has become a rational alternative for the treatment of CCC. In this context, different classes of drugs, cell therapies with dendritic cells or stem cells and gene therapy have shown potential to modulate systemic inflammation and myocarditis in CCC models. Based on that, the present review provides an overview of current reports regarding the use of immunomodulatory agents in treatment of CCC, bringing the challenges and future directions in this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available